Advertisement

Topics

Companies Related to "Frontier Pharma Ophthalmology Therapeutics Gene Therapies FirstinClass Targets" [Most Relevant Company Matches] RSS

12:37 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "Frontier Pharma Ophthalmology Therapeutics Gene Therapies FirstinClass Targets" found in our extensive corporate database of over 50,000 company records.

Showing "Frontier Pharma Ophthalmology Therapeutics Gene Therapies FirstinClass Targets" Companies 1–25 of 4,100+

Relevant

Kyn Therapeutics

Kyn Therapeutics is a biotechnology company advancing new immunometabolic therapies for cancer. A growing body of research indicates that key metabolites can exert broad suppressive or enhancing effects on the immune system through a complex network of cellular interactions, providing targets for new therapies that could significantly enhance patient respo...


Xcovery Vision

Xcovery Vision is an ophthalmology-focused subsidiary of Xcovery Holding, a clinical-stage company developing novel therapies for cancer and inflammatory diseases. Xcovery Vision's goal is to develop innovative therapies to address unmet healthcare needs and improve the standard of care in the field of ophthalmology. Xcovery Vision is developing a comprehe...

PTC Therapeutics Incorporated

PTC Therapeutics, Inc. discovers and develops small molecule drugs by applying its integrated RNA biology and chemistry platforms. PTC’s compounds modulate gene expression by selectively binding to either RNA targets or proteins that interact with RNA. This approach has progressed the Company’s drug discovery programs rapidly from targets to lead optimization. PTC’s pipeline includes program...


Frontier Airlines Holdings, Inc.

Frontier Airlines Holdings, Inc. is the parent company of Denver-based Frontier Airlines. Currently in its 15th year of operations, Frontier Airlines is the second-largest jet service carrier at Denver International Airport, employing approximately 5,000 aviation professionals. Frontier Airlines' mainline operation has 51 aircraft with one of the youngest Airbus fleets in North America. Frontier A...

Applied Therapeutics Inc.

Applied Therapeutics is a privately held biotechnology company, focused on developing transformative drugs in areas of high unmet medical need – fatal or debilitating diseases for which no therapies are approved. The company applies cutting-edge technology to validated drug targets that have failed to produce meaningful therapies in the past. Applied ...

Frontier Management, LLC

Frontier Management, LLC manages quality senior housing and services throughout the United States. The company has extensive expertise in retirement and assisted living, memory care, skilled nursing and nursing home management, as well as home health. Frontier’s inviting communities provide the comfort and service residents have come to expect. To con...

Frontier Utilities

Frontier Utilities, a retail electricity provider licensed in Texas since 2008, is a privately-held company with headquarters in Houston, Texas. Frontier Utilities serves residential and small commercial customers in all major deregulated areas of the state and has been providing affordable energy plans for several years. Frontier Utilities is committed to...

U3 Pharma AG

U3 Pharma AG is an emerging leader in targeted cancer drug development. The company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Prof. Axel Ullrich.U3 Pharma´s vision is to provide clinical oncologists with an arsenal of new targeted therapeutics that can be employed to turn cancer. an often life threatening disease, into a ...

OriGene Technologies Incorporated

OriGene, a gene discovery company, is engaged in the identification and validation of molecular drug targets. OriGene have developed a proprietary technology for high-throughput gene cloning and have identified numerous genes that are associated with the development of different human disorders. OriGene is actively engaged in establishing research alliances with pharmaceutical and biotech companie...

Ascent Therapeutics

Ascent Therapeutics is pioneering a new class of drugs called PepducinsTM. Pepducins are a breakthrough approach to targeting G-protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, CNS disorders and cardiovascular disease. Pepducin...

Lanthio Pharma

Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide technology to the discovery of novel peptide therapeutics with longer half-life and high receptor selectivity. Lanthio Pharma has already discovered several lanthipeptides for a number of GPCR targets, which is a focus area of the company.

Dimension Therapeutics

Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Launched by Fidelity Biosciences in 2013, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its adeno-associated virus (AAV) therapeutic discov...

CROMA-PHARMA GmbH

CROMA-PHARMA is a family owned, internationally orientated pharmaceutical company, based in Korneuburg, Austria. CROMA-PHARMA´s areas of activity are orthopedics, ophthalmology, dermatology and contract manufacturing. CROMA-PHARMA is dedicated to improving people’s quality of life through innovative, consistently simple and effective health solutio...

Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third ...

Zycos Incorporated

ZYCOS Inc. is a drug development company that is focused on converting genetic information into drugs, faster. The company's proprietary technology platform is comprised of gene expression vectors, polymer delivery systems and unique methods of antigen discovery and optimization. Integrating its technologies and in-house expertise, the company has formed a "plug and play" process to validate and o...

Frontier Communications

Frontier Communications Corporation (NYSE: FTR) is a Fortune 500 company included in the S&P 500 Index and offering voice, High-Speed Internet, video, wireless Internet data access, data security solutions, bundled offerings and specialized bundles for residential customers, small businesses and home offices, and advanced business communications solutions ...

Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process d...

Myonexus Therapeutics

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb girdle muscular dystrophies (LGMDs) based on research at Nationwide Children’s Hospital, a leader in neuromuscular gene therapy discovery and translational research. Myonexus Therapeutics’ pipeline includes three clinical stage g...

QLT PhotoTherapeutics Incorporated

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies to treat cancer, eye diseases and immune disorders. Combining expertise in ophthalmology, oncology and photodynamic therapy, QLT has commercialized two products to date, including Visudyne® therapy which is the most successfully launched ophthalmology product ever.

Enobia Pharma Inc.

Enobia Pharma Inc. is a private, Montreal based company focused on the development of therapeutics to treat serious bone disorders for which there are no drug therapies currently approved. ENB-0040, an investigational drug for the treatment of hypophosphatasia, is the Company's lead program. For more information, please visit www.enobia.com.

Exonhit Therapeutics Incorporated

ExonHit Therapeutics is a functional genomics and drug discovery company that develops sophisticated and innovative gene-based therapeutics (Ready for Development Compounds - RDCs ) and diagnostic products by using its unique proprietary qualitative gene profiling technology, DATAS™, based on alternative splicing.

Tranzyme Pharma

Tranzyme Pharma is a clinical-stage drug development company that discovers and develops novel small molecule macrocyclic drugs for both acute care (hospital-based) and chronic indications with significant unmet medical needs. The Company's pipeline is derived from its proprietary drug discovery (chemistry) technology, MATCH™, and targets products for...

Advanced Vision Therapies, Inc

Advanced Vision Therapies, Inc. (AVT) is focused on the treatment of sight-threatening eye diseases, such as age-related macular degeneration and finding a cure that works. The market, which is of a multi-billion dollar magnitude, and represents significant unmet medical needs, has been underserved by large pharma. Recent clinical trial data suggest that these diseases will be treatable, but with ...

Sequitur Incorporated

Sequitur, Inc. was founded in 1996 to develop innovative sequence-based compounds for functional genomics research, diagnostic and therapeutic applications. Sequitur's proprietary antisense technology can be employed to determine gene function and validate small molecule targets by specifically inhibiting gene expression. We also offer a line of products and services relating to gene expression...

Sangamo BioSciences

Sangamo BioSciences develops and markets novel transcription factors capable of regulating genes. The company’s powerful Universal Gene Recognition™ technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors tha...


More From BioPortfolio on "Frontier Pharma Ophthalmology Therapeutics Gene Therapies FirstinClass Targets"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks